Pharma giants create Asian cancer R&D group

Eli Lilly, Merck and Pfizer are joining forces to launch a new research group in Asia which will zero in on new therapies and diagnostics for the continent's most common cancer types. And the Asian Cancer Research Group-which will initially target lung and gastric cancers--will openly share their work with academic researchers in the field. "Through its work and the subsequent sharing of information, the ACRG hopes to empower researchers, foster innovation and improve the prognosis and treatment of patients with cancer," said Gary Gilliland, M.D., Ph.D., senior vice president and franchise head, oncology, Merck Research Laboratories. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.